866: Bringing Back Extinct Animals like the Woolly Mammoth and Dodo Bird

Episode Summary

Executive Summary: The episode explores Colossal Biosciences’ de-extinction work—especially woolly mammoths and dodos—as an example of how ambitious biotech can attract massive investment and generate valuable spin-off technologies. The host explains the science, business models, and broader implications, arguing that the pursuit of “impossible” goals can create breakthroughs in conservation, fertility, plastic cleanup, and computational biology.

Main Topics: Colossal Biosciences and de-extinction: Introduces Colossal Biosciences, its mission to bring back extinct species, and why its mammoth and dodo projects are generating attention and capital. How de-extinction works: Explains the technical workflow: genome mapping, comparison to living relatives, CRISPR editing, and embryo implantation into surrogate species. Commercialization through spin-offs: Shows how the company monetizes research by spinning out technologies like plastic-degrading microbes and computational biology tools. Conservation and biodiversity markets: Discusses applying de-extinction-adjacent tech to endangered species recovery and the emerging biodiversity credits market. Broader biotech and data science value: Frames the company as a case study in computational biology, machine learning, and precision gene editing producing large downstream value. Ambition as an innovation strategy: Argues that pursuing seemingly impossible goals can unlock technologies with wide societal and commercial applications.

Key Arguments: Huge funding and valuation suggest investors see de-extinction as a platform for multiple high-value technologies, not just a single moonshot. The de-extinction process depends on preserved DNA, a close living relative, and a suitable habitat, which limits candidates and makes dinosaurs implausible. Technologies developed for mammoth revival have immediate applications in fertility medicine, conservation, and environmental remediation. Colossal’s spin-offs and partnerships create alternative revenue paths before de-extinction itself is complete. The episode frames computational biology, machine learning, and gene editing as key enablers of a new biotech frontier. Ambitious scientific goals can produce innovations that become valuable in their own right, even if the original mission takes years to achieve.

Data Points: Series C funding: $200 million - Colossal Biosciences recently raised this amount in a Series C round. Valuation: Over $10 billion - The company’s post-round valuation was described as more than $10 billion. Valuation increase: Nearly seven-fold - The host notes the valuation has risen sharply compared with a couple of years earlier. Projected completion timeline: 2028 - The main de-extinction projects are said not to be completed until around this year. Number of surviving northern white rhinoceroses: 2 - Used as an example of an endangered species Colossal could help conserve. Spin-off ventures launched: 2 - Breaking and FormBio are cited as successful spin-offs already created by Colossal.

Pivotal Quotes: "Sometimes the most valuable innovations come not from trying to solve immediate market needs, but from pursuing seemingly impossible dreams." — John Crohn: The episode’s closing takeaway about innovation strategy. "Well-preserved DNA samples are critical for de-extinction, we also need a closely related living species that can serve as a surrogate and a suitable habitat needs to still exist" — John Crohn: Explaining the practical constraints on which extinct animals could realistically be revived. "an example of how computational biology, genetic algorithms, and advanced data analysis are transforming what we thought was possible" — John Crohn: Summarizing the data science significance of Colossal’s work.

Implications: De-extinction may be less important as a literal end goal than as a catalyst for breakthroughs in gene editing, fertility, conservation, and environmental tech. For listeners and industry, the lesson is to think bigger: moonshot science can create multiple commercial and societal wins.